AUM Biosciences adds Naz Haji to its Board of Advisors

AUM Biosciences (AUM), a Singapore-based company officially announced today the addition of Naz Haji to its Board of Advisors. AUM is focused on the development of innovative and affordable oncology medicines for cancers with high unmet medical need in Asia.

About Naz Haji

Naz Haji is a global Business Executive and Board Member with over 30 years of experience leading successful teams across mature and emerging markets within the life sciences and pharmaceutical services.

He is a multiple industry veteran with deep expertise not only in life sciences, pharma, energy, construction, manufacturing, aerospace, and consulting but additionally, the technologies that power these industries. He has served on multiple boards for both profit and nonprofit organizations across the globe. Most recently, he was Managing Director for IQVIA India, leading thousands of employees across multiple business lines.

Naz has led cross-cultural teams and organizations across the globe in numerous capacities. His geographic experience spans multiple locations within the US and Canada, Europe, Africa, and Asia. He has continuously driven change and compounded productivity while receiving numerous accolades for innovation, growth, and leadership. The technology and business divisions led by Naz have been consistently recognized by external industry bodies and he has contributed to multiple industry publications on business, leadership, and technology.

Today, Naz is the Chief Executive Officer and Founder of NH Advisory, supporting a wide range of companies in various capacities, including technology, market growth, and operations. Recognised for his experience and expertise, he is often quoted by local media and quite often on the stage at conferences and events. He serves on various boards and continues to be committed to life sciences and health care. The improvement of human life and conditions are at his core, and he is elated to be associated with companies like AUM Biosciences who share the same goal.

“Having witnessed patients and their families struggling to cope with cancer on a daily basis, it makes perfect sense that AUM, a progressive, flexible oncology focused biotech company, will pave a new and exciting path in addressing the needs of oncology patients in the Asia- Pacific region and also globally,” says Naz Haji, Board Member, AUM Biosciences.

Naz holds a Bachelor of Administrative Studies from York University in Toronto.

About AUM Biosciences

AUM Biosciences is an award-winning, oncology- focused biotechnology company that aims to accelerate the development of innovative, affordable cancer medicines for patients in Asia and around the world. AUM Biosciences focuses on early-stage development of innovative medicines for the treatment of Asian- prevalent cancers.

AUM Biosciences will have a specific focus on indications such as hepatocellular carcinoma, head and neck cancer, gastric cancer, cholangiocarcinoma, triple negative breast cancer, prostate and colorectal cancer. With a huge opportunity to identify targets for unmet medical needs, AUM Biosciences will partner and collaborate with leading research institutes, clinicians and pharmaceutical companies bringing new, affordable and effective therapies to patients in need. For more information, please visit www.aumbiosciences.com or email info@aumbiosciences.com.